REV Pharmaceuticals

REV Pharmaceuticals was a biotechnology company focused on the discovery and development of small molecule modulators of nuclear receptors, specifically the retinoic acid receptor-related orphan receptors (RORs). Founded in 2011 based on research from the Scripps Research Institute and Saint Louis University, the company targeted ROR gamma (RORγ) and ROR alpha (RORα) for the treatment of autoimmune, inflammatory, and metabolic diseases. Its lead programs focused on Th17-mediated conditions such as psoriasis and rheumatoid arthritis, as well as metabolic disorders like type 2 diabetes and obesity. The company utilized a proprietary screening platform to identify potent and selective small molecules that could regulate these key transcription factors. REV Pharmaceuticals was acquired by Gilead Sciences in 2015 to bolster Gilead's early-stage portfolio in inflammatory and metabolic therapeutic areas.